2023
Characterizing Persons With HIV/HCV Coinfection Who Remain Untreated for Hepatitis C at Four HIV Clinics in Connecticut (CT): Role of Multiple Overlapping Barriers at the Individual and Clinic System Levels
Zhao A, Wegener M, Brooks R, Mininberg L, Helou E, Maughan A, Villanueva M. Characterizing Persons With HIV/HCV Coinfection Who Remain Untreated for Hepatitis C at Four HIV Clinics in Connecticut (CT): Role of Multiple Overlapping Barriers at the Individual and Clinic System Levels. Health Promotion Practice 2023, 24: 1029-1038. PMID: 37439687, DOI: 10.1177/15248399231169793.Peer-Reviewed Original ResearchConceptsHIV/HCV coinfectionHepatitis C virusHCV coinfectionHIV clinicDirect-acting antiviral medicationsHIV transmission risk factorsPrimary care HIV clinicClinic-level barriersHCV elimination targetsChronic HCV infectionRetrospective chart reviewPatient-level barriersClinical practice patternsMedication-assisted treatmentTransmission risk factorsIllicit substance usePatient-specific issuesLack of transportationSubstance use problemsMental health issuesHCV cureHCV infectionHCV treatmentHepatitis CUntreated patients
2021
Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients
Sivakumar A, Madden L, DiDomizio E, Eller A, Villanueva M, Altice FL. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients. International Journal Of Drug Policy 2021, 101: 103570. PMID: 34954493, PMCID: PMC8685180, DOI: 10.1016/j.drugpo.2021.103570.Peer-Reviewed Original ResearchConceptsOpioid use disorderHepatitis C virusSyringe services programDifferentiated care modelPerson visitsC virusCare modelUse disordersInitiation of DAAChronic HCV infectionEvidence-based treatmentsCOVID-19Initial phlebotomyVirological responseHCV infectionHCV treatmentAdditional patientsElevated riskPatientsClient-centred approachPWIDHIVPerson contactTreatment demandLaboratory screening
2020
A Colocalized Hepatitis C Virus Clinic in a Primary Care Practice Improves Linkage to Care in a High Prevalence Population
Adamson PC, Miceli J, Shiferaw B, Villanueva MS, Canterino JE. A Colocalized Hepatitis C Virus Clinic in a Primary Care Practice Improves Linkage to Care in a High Prevalence Population. The American Journal Of Medicine 2020, 133: 705-712. PMID: 31987799, DOI: 10.1016/j.amjmed.2019.12.028.Peer-Reviewed Original ResearchConceptsChronic HCVPrimary care practicesClinic practiceHCV clinicChronic hepatitis C virus (HCV) infectionCare practicesHepatitis C virus infectionCascade of careHCV antibody testHCV testing dataC virus infectionChronic HCV infectionPrevalence of HCVPrimary care patientsHigh-prevalence populationsHCV cascadeHCV infectionCare patientsMultivariable analysisRetrospective studyClinic populationPrevalence populationsVirus infectionHigher oddsHCV
2019
Implementing a Comprehensive Hepatitis C Virus (HCV) Clinic Within a Human Immunodeficiency Virus Clinic: A Model of Care for HCV Microelimination
Rizk C, Miceli J, Shiferaw B, Malinis M, Barakat L, Ogbuagu O, Villanueva M. Implementing a Comprehensive Hepatitis C Virus (HCV) Clinic Within a Human Immunodeficiency Virus Clinic: A Model of Care for HCV Microelimination. Open Forum Infectious Diseases 2019, 6: ofz361. PMID: 31412130, PMCID: PMC6785669, DOI: 10.1093/ofid/ofz361.Peer-Reviewed Original ResearchDirect antiviral agentsHIV clinicHCV clinicEffective direct antiviral agentsHospital-based HIV clinicHCV treatment cascadeChronic HCV infectionCohort of patientsInitiation of treatmentActive drug useModel of careMental health issuesElectronic medical record templatesHCV careMicro-EliminationStandardized referralTreat populationHCV eliminationHCV infectionRetrospective reviewTreatment cascadeTreatment initiationFemale patientsTreatment algorithmMedical record templates
2017
Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients
Ogbuagu O, Hao R, Virata M, Villanueva M, Malinis M. Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients. F1000Research 2017, 6: 620. DOI: 10.12688/f1000research.11397.1.Peer-Reviewed Original ResearchHCV genotype 1 infectionGenotype 1 infectionHCV viral loadSOF/LDVViral loadSVR 12Treatment regimenGenotype 1Sustained virologic response 12 weeksYale New Haven Health SystemIU/HCV co-infected patientsVirologic response 12 weeksCo-infected patientsHCV treatment regimenMono-infected patientsSimilar viral loadsCompletion of therapyHCV genotype 1HIV viral loadSame treatment regimenSofosbuvir/ledipasvirStudy eligibility criteriaAntiretroviral therapyHCV infection